Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively degenerate. However, long-term analysis of human iPS cell-derived dopaminergic neurons in primate PD models has never been performed to our knowledge. Here we show that human iPS cell-derived dopaminergic progenitor cells survived and functioned as midbrain dopaminergic neurons in a primate model of PD (Macaca fascicularis) treated with the neurotoxin MPTP. Score-based and video-recording analyses revealed an increase in spontaneous movement of the monkeys after transplantation. Histological studies showed that the mature dopaminergic neurons extended dense neurites into the host striatum; this effect was consistent regardless of whether the cells were derived from patients with PD or from healthy individuals. Cells sorted by the floor plate marker CORIN did not form any tumours in the brains for at least two years. Finally, magnetic resonance imaging and positron emission tomography were used to monitor the survival, expansion and function of the grafted cells as well as the immune response in the host brain. Thus, this preclinical study using a primate model indicates that human iPS cell-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Morizane et al. and Kikuchi et al. both showed that an improvement of engraftment and reduced immune reaction were observed using MHC matching of iPSC-derived dopaminergic neurons in unlesioned non-human primates [98,99].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [99]
In the citing paper
“A comprehensive study of human iPSC-derived dopamine neuron progenitor cells expressing specific markers of the neural floor plate (CORIN+; FOXA2+; TUJ1+; PAX6−) and transplanted into a monkey model of Parkinson’s disease showed stronger evidence of behavioural benefits, of cellular integration of mature dopamine neurons within the putamen, and of extension of their dense neurites into the host st”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
In the citing paper
“Most of the transplanted cells expressed FOXA2 and a third expressed tyrosine hydroxylase consistent with mature functional dopamine neurons.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
Citations
Cites
Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Fast robust automated brain extraction
Smith, S. M. (2002) · Human Brain Mapping · doi:10.1002/hbm.10062 · Cited by 10,496
Zhang, Y., Brady, M., & Smith, S. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 6,982
A global optimisation method for robust affine registration of brain images
Jenkinson, M., & Smith, S. (2001) · Medical Image Analysis · doi:10.1016/s1361-8415(01)00036-6 · Cited by 6,872
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Cited by
Items 101–200 of 705
Parmar, M., Torper, O., & Drouin‐Ouellet, J. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14109 · Cited by 59
“…high relevance and important for the stem cell transplantation field is that iPSCs seem to carry the same differentiation potential as ESCs, and therefore can be used in a similar manner to generate authentic and functional DA neurons for transplantation (Kikuchi et al., 2017; Kriks et al., 2011).”
Self-citationGodbe, J. M., Freeman, R., Burbulla, L. F., Lewis, J. A., Krainc, D., & Stupp, S. I. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01585 · Cited by 51
Single-cell transfection technologies for cell therapies and gene editing
Duckert, B., Vinkx, S., Braeken, D., & Fauvart, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.068 · Cited by 53
Nakano-Kobayashi, A., Fukumoto, A., Morizane, A., Nguyen, D. T., Le, T. M., Hashida, K., Hosoya, T., Takahashi, R., Takahashi, J. B., Hori, O., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc1428 · Cited by 52
Self-citationAdvantages and Recent Developments of Autologous Cell Therapy for Parkinson’s Disease Patients
Osborn, T. M., Hallett, P. J., Schumacher, J. M., & Ole Isacson, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00058 · Cited by 54
“…are now available worldwide for midbrain differentiation that includes DA neurons (Cooper et al., 2010; Kriks et al., 2011; Sundberg et al., 2013; Kikuchi et al., 2017; Nolbrant et al., 2017) and protocols are being refined by use of xeno-free procedures and highest grade available reagents…”
BackgroundMethodResultInfluentialSingle-Cell RNA Sequencing in Parkinson’s Disease
Ma, S., & Lim, S. B. (2021) · Biomedicines · doi:10.3390/biomedicines9040368 · Cited by 62
Treating Parkinson’s disease by astrocyte reprogramming: Progress and challenges
Wei, Z. D., & Shetty, A. K. (2021) · Science Advances · doi:10.1126/sciadv.abg3198 · Cited by 54
Zheng, W., Li, Q., Zhao, C., Da, Y., Zhang, H., & Chen, Z. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00239 · Cited by 56
“…distribution, and function between species (Oberheim et al., 2006, 2009). hiPSCs are at the forefront of research in neurological diseases and are recognized as a source for generating autologous donor cells for disease modeling, drug discovery, and replacement therapy (Kikuchi et al., 2017).”
BackgroundDevelopment and Differentiation of Midbrain Dopaminergic Neuron: From Bench to Bedside
Wang, M., Ling, K., Tan, J. J., & Lu, C. (2020) · Cells · doi:10.3390/cells9061489 · Cited by 52
“Such discovery has also led to an in vivo testing of primate PD models, of which transplanting the ESC-derived mDA neurons showed promising improvement in motor function [65,71].”
BackgroundResultInfluentialStem-Cell-Based Therapy: The Celestial Weapon against Neurological Disorders
Zayed, M. A., Sultan, S., Alsaab, H. O., Yousof, S. M., Alrefaei, G. I., Alsubhi, N. H., Alkarim, S., Ghamdi, K. S. A., Bagabir, S. A., Jana, A., et al. (2022) · Cells · doi:10.3390/cells11213476 · Cited by 55
Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease
Cha, Y., Park, T.-Y., Leblanc, P. R., & Kim, K. (2023) · Journal of Movement Disorders · doi:10.14802/jmd.22141 · Cited by 51
Yuan, Y., Tang, X., Bai, Y., Wang, S., An, J., Wu, Y., Xu, Q., Zhang, Y. A., & Chen, Z. (2018) · Theranostics · doi:10.7150/thno.26643 · Cited by 46
“Compared to allogeneic DA precursors (fetal ventral mesencephalon tissue or ES-derived DA neural cells), autologous DA cells may be advantageous since they may circumvent immune recognition-associated problems [12, 13, 38, 39].”
BackgroundCellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
Jamebozorgi, K., Taghizadeh, E., Rostami, D., Pormasoumi, H., Barreto, G. E., Hayat, S. M. G., & Sahebkar, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1419-8 · Cited by 50
The Importance of Computational Modeling in Stem Cell Research
del Sol, A., & Jung, S. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.07.006 · Cited by 49
“Various clinical applications of autologous iPSCderived cell transplantation have been initiated and are currently ongoing [50,51]; however, a number of challenges must be overcome for this approach to reach its full potential.”
BackgroundNovel Approach to Stem Cell Therapy in Parkinson's Disease
Garitaonandia, I., Gonzalez, R., Sherman, G., Semechkin, A., Evans, A. H., & Kern, R. (2018) · Stem Cells and Development · doi:10.1089/scd.2018.0001 · Cited by 48
“[73,74].”
Duque, A., & Spector, R. (2019) · Brain Structure and Function · doi:10.1007/s00429-019-01917-6 · Cited by 45
Human stem cell models to study host–virus interactions in the central nervous system
Harschnitz, O., & Studer, L. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-020-00474-y · Cited by 47
Rather, H., Almousa, S., Craft, S., & Deep, G. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102088 · Cited by 46
Current therapeutic strategies in Parkinson’s disease: Future perspectives
Kim, T. Y., & Lee, B. D. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100274 · Cited by 59
“This strategy yields hPSC-derived mesDA neurons that exhibit robust survival, long-range axonal integration, and functional motor recovery in PD models (Chen et al., 2016; Kikuchi et al., 2017; Kirkeby et al., 2017).”
Biomarker‐Responsive Nanosystems for Chronic Disease Theranostics
Fu, Q., Yu, L., Wang, Y., Li, P., & Song, J. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206300 · Cited by 45
Uses for humanised mouse models in precision medicine for neurodegenerative disease
Nair, R., Corrochano, S., Gasco, S., Tibbit, C., Thompson, D., Maduro, C., Ali, Z., Fratta, P., Acevedo‐Arozena, A., Cunningham, T. J., et al. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09807-2 · Cited by 44
Adult Stem Cells and Induced Pluripotent Stem Cells for Stroke Treatment
Fernández‐Susavila, H., Bugallo-Casal, A., Castillo, J., & Campos, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00908 · Cited by 45
“Besides its neuroprotective or neuroreparative application, the use of iPSCs for stroke modeling has been poorly exploited mainly because this is a neurological pathology with multiple affected cells types and reduced genetic component, compared to other neurological diseases such as Alzheimer’s or Parkinson’s.”
BackgroundRecent advances in stem cells therapy: A focus on cancer, Parkinson’s and Alzheimer’s
Fleifel, D., Rahmoon, M. A., AlOkda, A., Nasr, M., Elserafy, M., & El‐Khamisy, S. F. (2018) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2018.09.002 · Cited by 44
“They continued to monitor their behavior for two years in an attempt to alleviate PD symptoms [75].”
BackgroundPatient-Derived Midbrain Organoids to Explore the Molecular Basis of Parkinson's Disease
Galet, B., Cheval, H., & Ravassard, P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01005 · Cited by 52
“Recent studies have demonstrated that stem cell-derived mDA neurons or mDA progenitors could indeed functionally integrate into striatonigral circuits (162), and provide some symptomatic relief in a nonhuman primate model of PD without forming tumors (163).”
BackgroundJusop, A. S., Thanaskody, K., Tye, G. J., Dass, S. A., Wan Kamarul Zaman, W. S., & Nordin, F. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1173433 · Cited by 39
Lin, Y., Sato, N., Hong, S., Nakamura, K., Ferrante, E. A., Yu, Z., Chen, M. Y., Nakamura, D. S., Yang, X., Clevenger, R. R., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.05.005 · Cited by 45
Stem cells and regenerative medicine for neural repair
Takahashi, J. B. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.03.006 · Cited by 43
Self-citationModeling Parkinson’s Disease Using Patient-specific Induced Pluripotent Stem Cells
Li, H., Jiang, H., Zhang, B., & Feng, J. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181353 · Cited by 50
“Another approach is to transplant human iPSC-derived neurons in rat brains [138] or even brains of non-human primates [139], which would enable more effective modeling of age-dependent”
BackgroundCurrent Developments in Cell Replacement Therapy for Parkinson’s Disease
Guo, X., Tang, L., & Tang, X. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.03.022 · Cited by 41
“1) (Kirkeby et al., 2017).”
BackgroundInfluentialMaterials for Neural Differentiation, Trans‐Differentiation, and Modeling of Neurological Disease
Gong, L., Cao, L., Shen, Z., Shao, L., Gao, S., Zhang, C., Lü, J., & Li, W. (2018) · Advanced Materials · doi:10.1002/adma.201705684 · Cited by 41
Marotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 42
“More recently, both human and non-human primate iPSC-derived DA neurons could function properly following transplantation back into PD non-human primate models [34,172], highlighting the potential for success in future dopamine replacement studies based on iPSC-derived neurons.”
BackgroundCell Therapies for Spinal Cord Injury: Trends and Challenges of Current Clinical Trials
Bartlett, R. D., Burley, S., Ip, M. M. T., Phillips, J. B., & Choi, D. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa149 · Cited by 44
Deconstructing and reconstructing the human brain with regionally specified brain organoids
Xiang, Y., Çakır, B., & Park, I. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.023 · Cited by 42
Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease
Долгачева, Л. П., Зинченко, В. П., & Goncharov, N. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113043 · Cited by 51
A Chemical Recipe for Generation of Clinical-Grade Striatal Neurons from hESCs
Wu, M., Zhang, D., Bi, C., Mi, T., Zhu, W., Xia, L., Teng, Z., Hu, B., & Wu, Y. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.08.005 · Cited by 41
Brazdis, R.-M., Alecu, J. E., Marsch, D., Dahms, A., Simmnacher, K., Lörentz, S., Brendler, A., Schneider, Y., Marxreiter, F., Roybon, L., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa039 · Cited by 37
“In line with our results, previous studies reported the similar efficiency of cortical glutamatergic differentiation (32) and midbrain dopaminergic neuronal differentiation of iPSCs from healthy individuals (33), idiopathic (34) or genetic PD patients (26,35,36).”
ResultHabib, A., Jovanovich, N., Hoppe, M., Ak, M., Mamindla, P., Colen, R. R., & Zinn, P. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071411 · Cited by 43
“911, sensitivity: 85%, specificity: 85%) [34].”
Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia
Albert, K., Niskanen, J., Kälvälä, S., & Lehtonen, Š. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094334 · Cited by 48
“Human iPSC transplant has been successful in a non-human primate model of PD [175] and, last year, a study was published with a human patient [176].”
BackgroundWu, J., Chai, T., Zhang, H., Huang, Y., Perry, S. W., Li, Y., Duan, J., Tan, X., Hu, X., Liu, Y., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01836-x · Cited by 41
“The sample sizes (n = 6/every group) were chosen based on the data of previous NHP studies [17, 18], and our previous works on behavior and biochemical measures in M.”
MethodBerlet, R., Cabantan, D. A. G., Gonzales-Portillo, D., & Borlongan, C. V. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.798826 · Cited by 43
Birtele, M., Sharma, Y., Storm, P., Kajtez, J., Wahlestedt, J. N., Sozzi, E., Nilsson, F., Stott, S., He, X., Mattsson, B., et al. (2022) · Development · doi:10.1242/dev.200504 · Cited by 38
Self-citationCell therapy for Parkinson’s disease with induced pluripotent stem cells
Morizane, A. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-023-00269-3 · Cited by 59
“4 million cells were transplanted unilaterally, and an average of 64,000±49,000 dopaminergic neurons survived [6].”
BackgroundSelf-citationTherapeutic Strategies for Immune Transformation in Parkinson’s Disease
Saleh, M., Marković, M., Olson, K. E., Gendelman, H. E., & Mosley, R. L. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223278 · Cited by 44
Recent Advances: Decoding Alzheimer’s Disease With Stem Cells
Fang, Y., Gao, T., Zhang, B., & Pu, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00077 · Cited by 42
“Apart from the human-mice chimeric model (Espuny-Camacho et al., 2017), human iPSC-derived dopaminergic neurons were transplanted into a primate Parkinson’s disease model (Kikuchi et al., 2017).”
BackgroundGrudina, C., Kouroupi, G., Nonaka, T., Hasegawa, M., Matsas, R., & Zurzolo, C. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104609 · Cited by 39
Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling
Beghini, D. G., Kasai-Brunswick, T. H., & Henriques‐Pons, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042392 · Cited by 42
Huang, C., Sivalingam, K., Shibu, M. A., Liao, P., Ho, T., Kuo, W., Chen, R., Day, C. H., Viswanadha, V. P., & Ju, D. (2020) · Nutrients · doi:10.3390/nu12061707 · Cited by 37
New trends in cellular therapy
Okano, H., & Sipp, D. (2020) · Development · doi:10.1242/dev.192567 · Cited by 39
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Buttery, P. C., & Barker, R. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00940-4 · Cited by 44
Seo, J., Lee, Y., Kim, B. S., Park, J., Yang, S., Yoon, H., Yoo, J., Park, H. S., Hong, J. J., Koo, B., et al. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.037 · Cited by 36
Stauske, M., Rodríguez-Polo, I., Haas, W., Knorr, D. Y., Borchert, T., Streckfuß‐Bömeke, K., Dressel, R., Bartels, I., Tiburcy, M., Zimmermann, W., et al. (2020) · Cells · doi:10.3390/cells9061349 · Cited by 36
“These studies include the testing of human xenografts [17,19,20,24] and NHP allo- as well as autograft [16,21,23,24].”
BackgroundSekine, K., Ogawa, S., Tsuzuki, S., Kobayashi, T., Ikeda, K., Nakanishi, N., Takeuchi, K., Kanai, E., Otake, Y., Okamoto, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73908-1 · Cited by 36
Nemeth, C. L., Fine, A. S., & Fatemi, A. S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.003 · Cited by 42
Sheta, R., Teixeira, M., Idi, W., Pierre, M., Jacquet, A. D. R., Émond, V., Zorca, C. E., Vanderperre, B., Durcan, T. M., Fon, E. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22158-4 · Cited by 39
Advances and Applications of Brain Organoids
Li, Y., Zeng, P.-M., Wu, J., & Luo, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01065-2 · Cited by 40
“Because of the rarity and difficulty in obtaining human tissues, some studies have used stem cell induction technology in vitro to induce neurons and glial cells for the mechanistic investigation of NDDs [97, 98].”
BackgroundProgress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson’s Disease
Chen, W., Huang, Q., Ma, S., & Li, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00389 · Cited by 38
Generation of Transgenic Cynomolgus Monkeys Overexpressing the Gene for Amyloid-β Precursor Protein
Seita, Y., Morimura, T., Watanabe, N., Iwatani, C., Tsuchiya, H., Nakamura, S., Suzuki, T., Yanagisawa, D., Tsukiyama, T., Nakaya, M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191081 · Cited by 36
“Therefore, they have been used widely for modeling human disorders, including Parkinson’s disease [13].”
MethodNon-Coding RNAs in the Brain-Heart Axis: The Case of Parkinson’s Disease
Acharya, S., Salgado‐Somoza, A., Stefanizzi, F. M., Lumley, A. I., Zhang, L., Glaab, E., May, P., & Devaux, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186513 · Cited by 36
“As an example, iPSCs may be used not only to improve the diagnosis of PD but also to treat this disorder through genetic reprogramming [195].”
MethodGarcía‐León, J. A., Cáceres-Palomo, L., Sánchez‐Mejías, E., Mejias‐Ortega, M., Nuñez‐Diaz, C., Fernandez-Valenzuela, J. J., Sanchez-Varo, R. M., Dávila, J. C., Vitórica, J., & Gutiérrez, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186867 · Cited by 37
“In addition, knowledge about the specific signals that predominate in different brain region and are responsible for the generation and development of different neuronal subtypes has allowed the development of specific protocols for the derivation of specific neuronal subtypes as dopaminergic [26], glutamatergic, GABA…”
BackgroundFunction and regulation of corin in physiology and disease
Dong, N., Niu, Y., Chen, Y., Sun, S., & Wu, Q. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190760 · Cited by 35
Jury, M., Matthiesen, I., Boroojeni, F. R., Ludwig, S. L., Civitelli, L., Winkler, T. E., Selegård, R., Herland, A., & Aili, D. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102097 · Cited by 37
Integrated generation of induced pluripotent stem cells in a low-cost device
Lin, H., Li, Q., Du, Q., Wang, O., Wang, Z., Akert, L., Carlson, M. A., Zhang, C., Subramanian, A., Zhang, C., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.027 · Cited by 36
Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?
Salado-Manzano, C., Perpiñá, U., Straccia, M., Molina-Ruiz, F. J., Cozzi, E., Rosser, A., & Canals, J. M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00250 · Cited by 35
Li, D., Huang, L., Zhang, C.-P., Li, Q., & Wang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.890509 · Cited by 42
ALIX increases protein content and protective function of iPSC-derived exosomes
Sun, R., Liu, Y., Lu, M., Ding, Q., Wang, P., Zhang, H., Tian, X., Lu, P., Meng, D., Sun, N., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01767-z · Cited by 35
Collo, G., Mucci, A., Giordano, G. M., Pich, E. M., & Galderisi, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00632 · Cited by 38
An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation
Serva, S. N., Bernstein, J., Thompson, J. A., Kern, D. S., & Ojemann, S. G. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.863921 · Cited by 41
“Humaninduced PSCs have been shown to survive and function as midbrain dopaminergic neurons in a primate model of PD (100).”
BackgroundPark, T.-Y., Jeon, J., Cha, Y., & Kim, K. (2024) · Cell Research · doi:10.1038/s41422-024-00971-y · Cited by 38
iPSC-based cell replacement therapy: from basic research to clinical application
Takahashi, J. B. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.01.015 · Cited by 37
Self-citationNon-engineered and Engineered Adult Neurogenesis in Mammalian Brains
Lei, W., Li, W., Ge, L., & Chen, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00131 · Cited by 38
Brot, S., Thamrin, N. P., Bonnet, M., Francheteau, M., Patrigeon, M., Belnoue, L., & Gaillard, A. (2022) · Cells · doi:10.3390/cells11101596 · Cited by 35
“Other groups transplanted the progenitors later, at day 28 mDA [20,40], or at relatively early stage, at day 16 mDA [22,34,39,53,64,65].”
BackgroundNishimura, K., Yang, S., Lee, K. W., Ásgrímsdóttir, E. S., Nikouei, K., Pasławski, W., Gnodde, S., Lyu, G., Hu, L., Saltó, C., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.10.016 · Cited by 33
“, 2020), as well as PD cell replacement therapy (Adler et al., 2019; Arenas et al., 2015; Doi et al., 2020; Kikuchi et al., 2017; Kim et al., 2021; Kirkeby et al., 2017; Moriarty et al., 2022; Schweitzer et al., 2020; Tao et al., 2021).”
BackgroundInterfacing cells with microengineered scaffolds for neural tissue reconstruction
Accardo, A., Cirillo, C., Lionnet, S., Vieu, C., & Loubinoux, I. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.07.020 · Cited by 34
Neurogenic tissue nanotransfection in the management of cutaneous diabetic polyneuropathy
Roy, S., Sen, C. K., Ghatak, S., Higuita‐Castro, N., Palakurti, R., Nalluri, N., Clark, A. R., Stewart, R., Gallego‐Perez, D., Prater, D. N., et al. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102220 · Cited by 30
Zammit, M. D., Tao, Y., Olsen, M. E., Metzger, J. M., Vermilyea, S., Bjornson, K. J., Slesarev, M. S., Block, W. F., Fuchs, K., Phillips, S., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00683-5 · Cited by 34
“When evaluating the immune response to these cells via [(11)C]PK11195 PET, the authors described either no inflammation or mild inflammation in grafted areas [52].”
InfluentialJang, S. E., Qiu, L., Chan, L. L., Tan, E., & Zeng, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.558532 · Cited by 35
“In PD studies, the quality of iPSC-derived DA neurons was highly similar to that of hESCs (Cooper et al., 2010; Doi et al., 2014; Kikuchi et al., 2017; Lehnen et al., 2017), and human leukocyte antigen (HLA)-matched allogeneic neural transplantation into monkeys increased the efficacy of cell survival and function (Mo…”
BackgroundGeneration of human A9 dopaminergic pacemakers from induced pluripotent stem cells
Li, H., Jiang, H., Li, H., Li, L., Yan, Z., & Feng, J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01628-1 · Cited by 35
“Consistent with this, two independent groups have sought to optimize a well-recognized method [18] by using an appropriate seeding pattern [30, 31] or by sorting CORIN neural progenitors to enrich TH neurons [32, 33].”
BackgroundMethodCui, X., Li, X., Zheng, H., Su, Y., Zhang, S., Li, M., Hao, X., Zhang, S., Hu, Z., Xia, Z., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00799-8 · Cited by 41
“The extent of recovery in the neurologic score and spontaneous movement of PD monkeys grafted with iPSC-derived cells was similar or lower than those produced by L-DOPA drug administration 154 .”
BackgroundResultPerspectives of RAS and RHEB GTPase Signaling Pathways in Regenerating Brain Neurons
Schöneborn, H., Raudzus, F., Coppey, M., Neumann, S., & Heumann, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124052 · Cited by 33
“Experiments show that human induced pluripotent stem cell (iPSC)-derived dopaminergic progenitor cells survived and functioned as midbrain dopaminergic neurons in a primate model of Parkinson’s disease (Macaca fascicularis) [290].”
Arjmand, B., Tayanloo-Beik, A., Heravani, N. F., Alaei, S., Payab, M., Alavi-Moghadam, S., Goodarzi, P., Gholami, M., & Larijani, B. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00396 · Cited by 35
Gordián‐Vélez, W. J., Chouhan, D., España, R. A., Chen, H.-C. I., Burdick, J. A., Duda, J. E., & Cullen, D. K. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.07.016 · Cited by 33
Induced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-6016-0_40-1 · Cited by 29
Lv, S., He, E., Luo, J., Liu, Y., Liang, W. J., Xu, S., Zhang, K., Yang, Y. F., Wang, M., Song, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202301828 · Cited by 34
Induced pluripotent stem cell‐based modeling of mutant LRRK 2‐associated Parkinson's disease
Weykopf, B., Haupt, S., Jungverdorben, J., Flitsch, L. J., Hebisch, M., Liu, G., Suzuki, K., Belmonte, J. C. I., Peitz, M., Blaess, S., et al. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14345 · Cited by 32
“spontaneous spiking at 1–3 Hz; ‘pacemaking activity’) and the ability to function as midbrain dopaminergic neurons in culture slices and upon transplantation in animal models (Kikuchi et al., 2017; Kirkeby et al., 2012; Kriks et al., 2011).”
BackgroundGarcía‐León, J. A., Vitórica, J., & Gutiérrez, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0520 · Cited by 31
HMGB1 and Caveolin-1 related to RPE cell senescence in age-related macular degeneration
Sun, S., Cai, B., Li, Y., Su, W., Zhao, X., Gong, B., Li, Z., Zhang, X., Wu, Y., Chen, C., et al. (2019) · Aging · doi:10.18632/aging.102039 · Cited by 28
Yang, W., Hao, W., Meng, Z., Ding, S., Li, X., Zhang, T., Huang, W., Xu, L., Zhang, Y., Yang, J. M., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02128-5 · Cited by 29
Automatic identification of small molecules that promote cell conversion and reprogramming
Napolitano, F., Rapakoulia, T., Annunziata, P., Hasegawa, A., Cardon, M., Napolitano, S., Vaccaro, L., Iuliano, A., Wanderlingh, L. G., Kasukawa, T., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.03.028 · Cited by 33
Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases
Trudler, D., Ghatak, S., & Lipton, S. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158196 · Cited by 31
The Role of Cellular Defense Systems of Ferroptosis in Parkinson’s Disease and Alzheimer’s Disease
Chu, J., Li, J., Sun, L., & Wei, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814108 · Cited by 31
“The main pathological feature of the disease is the marked and progressive degeneration of dopaminergic neurons in the substantia nigra [83], which is associated with systemic progressive iron accumulation [84]; thus, dopamine depletion in the striatum, loss of neuromelanin, and the appearance of intracellular Lewy bo…”
BackgroundFiorenzano, A., Sozzi, E., Parmar, M., & Storm, P. (2021) · Cells · doi:10.3390/cells10061366 · Cited by 32
Self-citationHua, Y., Yoshimochi, K., Li, J., Takekita, K., Shimotsuma, M., Li, L., Qu, X., Zhang, J., Sawa, Y., Liu, L., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02879-z · Cited by 29
“This AK02N-(LM511-E8) combination is expandable and reproducible and has been widely used for the propagation of clinical-grade hiPSCs [9, 29].”
BackgroundLi, H., Wei, J., Pan, L., Zhang, Y., Guo, L., Qin, D., Yin, Y., Hu, X., & Wang, Z. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.06.077 · Cited by 30
Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies
Henchcliffe, C., & Parmar, M. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181488 · Cited by 29
Self-citationOh, S., Jeong, Y.-W., Choi, W., Noh, J., Lee, S., Kim, H. S., & Song, J. (2020) · Stem Cells International · doi:10.1155/2020/4061516 · Cited by 30
Stem Cell Therapy for Repair of the Injured Brain: Five Principles
Rust, R., & Tackenberg, C. (2022) · The Neuroscientist · doi:10.1177/10738584221110100 · Cited by 25
“For instance, iPSC-derived dopaminergic progenitor cells have shown promising results in a primate model of Parkinson disease, which involves the degeneration of dopaminergic neurons in the substantia nigra (Kikuchi and others 2017).”
BackgroundLi, J., Li, N., Wei, J., Feng, C. L., Chen, Y., Chen, T., Ai, Z., Zhu, X., Ji, W., & Li, T. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00440-6 · Cited by 28
“Given that younger monkeys often spontaneously recover over time after MPTP treatments 36 – 39 , we chose 8 – 15-year-old rhesus macaques (Supplementary Table 1) to generate stable PD models and assessed the animals ’ parkinsonism using a clinical PD score, spontaneous locomotor activity, and a fi…”
Clinical translation of pluripotent stem cell-based therapies: successes and challenges
Christiansen, J. R., & Kirkeby, A. (2024) · Development · doi:10.1242/dev.202067 · Cited by 29
Cell therapy for Parkinson’s disease with induced pluripotent stem cells
Morizane, A. (2019) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001235 · Cited by 30
Self-citationWoolf, A. S. (2019) · Kidney International · doi:10.1016/j.kint.2019.04.040 · Cited by 28
Metadata
- Authors
- Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., Morita, S., Yamamoto, M., Okita, K., Nakagawa, M., Parmar, M., & Takahashi, J.
- Affiliations
- Kyoto University (JP)
- RIKEN (JP)
- Lund University (SE)
- Corresponding author
- Takahashi, Jun
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7669
- Pages
- 592-596
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2751466955
- Cited by
- 702
- References
- 48
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 74 · 2023: 69 · 2022: 91 · 2021: 89 · 2020: 123 · 2019: 88 · 2018: 75 · 2017: 6
- FWCI
- 32.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15H02502, 15H02540, 16H03306, 15K12779, 16H03300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, dopaminergic neurons, induced pluripotent stem cells, cell transplantation, nonhuman primate model, Macaca fascicularis, MPTP-induced neurotoxicity, midbrain dopaminergic neurons, spontaneous movement, neurite outgrowth, corin, tumor formation, cell survival, cell tracking, immune response, cell therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Cell Survival, Disease Models, Animal, Humans, Macaca fascicularis, Magnetic Resonance Imaging, Male, Mesencephalon, Movement, Parkinson Disease, Serine Endopeptidases, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurites, Neostriatum, Regenerative Medicine, Cell Proliferation, Positron-Emission Tomography, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.